ZEGFROVY

LaunchSM

sunvozertinib

NDAORALTABLETPriority Review

Approved

Jul 2025

Lifecycle

Launch

Competitive Pressure

0/100

Loss of Exclusivity

LOE Date

Jan 28, 2039

157 months away

Patent Expiry

Jan 28, 2039

Exclusivity Expiry

Jul 2, 2030

Patent Records (3)

Patent #	Expiry	Type	Use Code
11007198	Jan 28, 2039	SubstanceProduct	—
11504375	Jan 28, 2039	SubstanceProduct	U-3220
11896597	Jan 28, 2039	SubstanceProduct	U-3220

External Resources

FDA approval history

Drug nomenclature & identifiers